Advertisement

Reactions Weekly

, Volume 1743, Issue 1, pp 83–83 | Cite as

Elvitegravir/raltegravir

Acquired antiretroviral resistance: 9 case reports
Case report
  • 17 Downloads
Author Information

An event is serious (based on the ICH definition) when the patient outcome is:

  • * death

  • * life-threatening

  • * hospitalisation

  • * disability

  • * congenital anomaly

  • * other medically important event

In a study of 99 patients, who underwent genotypic drug resistance testing in South Korea (between October 2014 and April 2017), 9 men aged 30−56 years were described, who acquired resistance to integrase strand transfer inhibitor (INSTI)-based antiretroviral therapy (ART) following treatment with elvitegravir or raltegravir for HIV-1 infection [dosages, routes and durations of treatments to reactions onsets not stated].

Patient A: A 44-year-old man, who was diagnosed with HIV-1 infection and who had been receiving raltegravir along with concomitant tenofovir disoproxil fumarate and emtricitabine, was included in a study. He subsequently underwent genotypic drug resistance test, which revealed acquaintance of INSTI-major mutation of Y143C. It was suspected that the exposure to...

Reference

  1. Jeong W, et al. Integrase Strand Transfer Inhibitor Resistance Mutations in Antiretroviral Therapy-Naive and Treatment-Experienced HIV Patients in South Korea. AIDS Research and Human Retroviruses 35: 213-216, No. 2, Feb 2019. Available from: URL: http://doi.org/10.1089/aid.2018.0213 - South KoreaCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2019

Personalised recommendations